• Atrial fibrillation or flutter, paroxysmal or sustained not due to a reversible cause, and eligible to receive anticoagulation therapy

• Patient must satisfy one or both of the following categories of risk factors:
  • Age ≥75 years at the time of screening
  • History of a clinical symptomatic stroke of any type.

• OR

• Patient must satisfy two or more of the following categories of risk factors:
  • Age between 65 and 74 years
  • Hypertension
  • Diabetes mellitus
  • Atherosclerotic vascular disease meeting one or more of the following criteria: a) Lower extremity PAD or b) prior major vascular amputation, peripheral bypass, or peripheral percutaneous
  • And/Or CAD, MI, CABG, PCI

• Does not have a history of any of the following only if within 3 months of randomization: primary hemorrhagic stroke, hemorrhagic transformation of an ischemic stroke, subarachnoid hemorrhage, subdural hematoma, spinal cord hemorrhage.

• Does not have any condition other than AF that requires chronic anticoagulation
• Does not have current active liver disease (eg, acute hepatitis, known cirrhosis), including participants receiving antiviral treatment for hepatitis.

• There will be about 20 office visits over about 4 years
• Patients may be compensated up to $70 per office visit
• Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
• Patients will be directed to their own doctor for normal care/non-study related health concerns

• Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m ²)
• Are either
  • individuals ≥40 years of age with established cardiovascular disease (CVD).
    • CVD is defined as meeting at least one of the following:
      • Coronary artery disease
      • Cerebrovascular disease
  • Peripheral arterial disease OR
  • individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)
    • women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or
    • women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening. Are on a stable treatment of at least 1 antihyperglycemic medication, for at least 3 months

• Do not have type 1 or type 2 diabetes
• Do not have history of ketoacidosis, or hyperosmolar state/coma
• Do not have class IV heart failure
• Are not using or have not used a GLP-1 within 3 months

• There will be about 27 study visits over about 5 years and 5 months
• Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
• Patients will be directed to their own doctor for normal care/non-study related health concerns

• 55 years of age or older
• Body mass index (BMI) ≥ 30
  1. Established CVD as evidenced by at least one of the following: Prior myocardial infarction, prior stroke (ischemic or hemorrhagic stroke), or Symptomatic peripheral arterial disease (PAD)

• If diabetic:
  • Diagnosed with type 2 diabetes ≥ 180 days ago
  • HbA1c 7%-10%

• No planned coronary, carotid or peripheral artery revascularization
• Not being treatmed with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days
• No chronic or intermittent hemodialysis or peritoneal dialysis

• There will be about 22 study visits over about 3 years
• Patients may be compensated up to $1,100.00 if all visits are completed
• Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
• Patients will be directed to their own doctor for normal care/non-study related health concerns

• Male or female over the age of 18
• Diagnosis of Parkinson’s disease
• Has Internet access to provide data online

For more information please visit:  www.foxinsight.org/clinic

• Surveys on health-related topics to be completed every 3 months for 5 years
• Optional, one-time surveys and sub-studies including genetic testing and counseling at no cost
• Appointment reminders and physician reports online for patients

• 18 years of age or older
• Diagnosed with type 2 diabetes ≥ 180 days ago
• Stable daily dose(s) ≥ 90 days of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose: metformin with or without an SGLT2 inhibitor.
• Do not have renal impairment
• No treatment with any medication for the indication of diabetes or obesity other than metformin with or without SGLT2 inhibitor within 90 days
• No planned (during the study period) obesity treatment with surgery or a weight loss device.

• Patients will remain on their current diabetes medication regardless of treatment group
• There will be about 14 office visits and 7 phone visits over about 18 months
• Patients may be compensated up to $55 per office visit and $25 per phone visit if all visits are completed
• Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
• Patients will be directed to their own doctor for normal care/non-study related health concerns

• 18 years of age or older
• Diagnosed with type 2 diabetes ≥ 180 days ago
• Stable daily dose(s) ≥ 90 days of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose: metformin with or without an SGLT2 inhibitor.
• Does not have renal impairment
• No treatment with any medication for the indication of diabetes or obesity other than metformin with or without SGLT2 inhibitor within 90 days
• No planned (during the study period) obesity treatment with surgery or a weight loss device.

• Patients will remain on their current diabetes medication regardless of treatment group
• There will be about 19 office visits and 8 phone visits over about 18 months
• Patients may be compensated up to $55 for office visits and $20 for phone visits if all visits are completed
• Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
• Patients will be directed to their own doctor for normal care/non-study related health concerns